SUSANNA ULAHANNAN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- PONCA CITY, OK
- NPI
- 1033369988
- Received
- $44,690 in 94 records, 2019 to 2025 ($39,107 general, $5,583 research)
- As principal investigator
- $8,250,087 of research payments to others in 1,980 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 9 | $597 |
| 2024 | General payment | 11 | $1,537 |
| 2023 | General payment | 18 | $4,133 |
| 2022 | General payment | 6 | $5,885 |
| 2021 | General payment | 8 | $11,030 |
| 2020 | General payment | 4 | $3,689 |
| 2019 | General payment | 34 | $12,232 |
| 2019 | Research payment | 4 | $5,583 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Boehringer Ingelheim International GmbH | 14 | $15,231 | 2019–2022 |
| Incyte Corporation | 16 | $6,785 | 2019–2021 |
| Eisai Inc. | 4 | $5,094 | 2020–2023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $4,505 | 2019 |
| AstraZeneca Pharmaceuticals LP | 10 | $4,171 | 2022–2025 |
| Exelixis Inc. | 14 | $3,338 | 2022–2024 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $1,615 | 2019 |
| Merck Sharp & Dohme LLC | 12 | $1,043 | 2019–2023 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 2 | $999 | 2020 |
| Regeneron Pharmaceuticals, Inc. | 3 | $730 | 2019 |
| Eli Lilly and Company | 1 | $402 | 2019 |
| ARRAY BIOPHARMA INC | 2 | $155 | 2024–2025 |
| PFIZER INC. | 5 | $143 | 2023–2025 |
| HISTOSONICS, INC. | 1 | $135 | 2025 |
| Caris MPI, Inc. | 1 | $133 | 2025 |
| Gilead Sciences, Inc. | 1 | $99 | 2024 |
| Genentech USA, Inc. | 1 | $25 | 2024 |
| Alcresta Therapeutics, Inc. | 1 | $25 | 2024 |
| Astellas Pharma US Inc | 1 | $23 | 2023 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 | 2024 |
| Genentech, Inc. | 1 | $14 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 17 | $17,881 |
| Consulting Fee | 7 | $15,055 |
| Research payment | 4 | $5,583 |
| Travel and Lodging | 13 | $3,633 |
| Food and Beverage | 47 | $2,363 |
| Education | 6 | $173 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-09-27 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-27 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-25 | AstraZeneca Pharmaceuticals LP | $140 | Food and Beverage | In-kind items and services | ATACAND Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-08-26 | HISTOSONICS, INC. | $135 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-17 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-10 | PFIZER INC. | $85 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-05-20 | Caris MPI, Inc. | $133 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-03-11 | ARRAY BIOPHARMA INC | $16 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2024-11-26 | Alcresta Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | RELIZORB Device, GASTROENTEROLOGY | 2024 | |
| 2024-08-27 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Perjeta Biological, BioOncology | 2024 | |
| 2024-07-25 | Ipsen Biopharmaceuticals, Inc | $16 | Education | In-kind items and services | Onivyde Drug, Oncology | 2024 | |
| 2024-06-20 | Gilead Sciences, Inc. | $99 | Education | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-05-22 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-20 | PFIZER INC. | $11 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-05-20 | PFIZER INC. | $7 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-03-06 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-02-16 | Exelixis Inc. | $27 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2024 | |
| 2024-01-19 | ARRAY BIOPHARMA INC | $138 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-19 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | 2024 | ||
| 2023-11-07 | Merck Sharp & Dohme LLC | $6 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-23 | Exelixis Inc. | $30 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-10-23 | Exelixis Inc. | $30 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-10-23 | Exelixis Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-09-29 | Exelixis Inc. | $85 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-29 | Exelixis Inc. | $35 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-29 | Exelixis Inc. | $27 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-29 | Exelixis Inc. | $27 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-28 | Exelixis Inc. | $320 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-28 | Exelixis Inc. | $106 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-27 | Exelixis Inc. | $456 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-27 | Exelixis Inc. | $260 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-27 | Exelixis Inc. | $260 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-07 | PFIZER INC. | $25 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2023 | |
| 2023-09-07 | PFIZER INC. | $12 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2023 | |
| 2023-08-15 | Astellas Pharma US Inc | $23 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-24 | Eisai Inc. | $2,280 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-01-20 | Eisai Inc. | $125 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2022-10-17 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-06-30 | Boehringer Ingelheim International GmbH | $692 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2022 | ||
| 2022-06-30 | Boehringer Ingelheim International GmbH | $484 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2022 | ||
| 2022-06-30 | Boehringer Ingelheim International GmbH | $299 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2022 | ||
| 2022-06-03 | Exelixis Inc. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-01-26 | AstraZeneca Pharmaceuticals LP | $2,740 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2021-11-10 | Boehringer Ingelheim International GmbH | $695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-11-10 | Boehringer Ingelheim International GmbH | $556 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-09-20 | Boehringer Ingelheim International GmbH | $2,094 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-09-16 | Boehringer Ingelheim International GmbH | $4,847 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-07-15 | Boehringer Ingelheim International GmbH | $2,094 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-06-04 | Boehringer Ingelheim International GmbH | $505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-06-04 | Boehringer Ingelheim International GmbH | $217 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2021 | ||
| 2021-05-06 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | PEMAZYRE Drug, Hepatology (Liver, Pancreatic, Gall Bladder) | 2021 | |
| 2020-07-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | $562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2020 | ||
| 2020-02-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | $437 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2020 | ||
| 2020-02-05 | Eisai Inc. | $2,565 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2020 | |
| 2020-01-16 | Eisai Inc. | $124 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2020 | |
| 2019-12-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | Vitrakvi Drug, Oncology | 2019 | |
| 2019-11-22 | Boehringer Ingelheim International GmbH | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-11-12 | Bayer Healthcare Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | Vitrakvi Drug, Oncology | 2019 | |
| 2019-11-01 | Boehringer Ingelheim International GmbH | $972 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-10-29 | Boehringer Ingelheim International GmbH | $972 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-10-12 | Incyte Corporation | $4,920 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $120 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $49 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $47 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $24 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $24 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $11 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | Incyte Corporation | $4 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Incyte Corporation | $1,052 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Incyte Corporation | $289 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Incyte Corporation | $120 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Incyte Corporation | $30 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-09-06 | Genentech, Inc. | $14 | Food and Beverage | In-kind items and services | Non-Covered Product Drug, None | 2019 | |
| 2019-07-22 | Boehringer Ingelheim International GmbH | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-06-02 | Regeneron Pharmaceuticals, Inc. | $485 | Research payment | In-kind items and services | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2019 | |
| 2019-05-29 | Regeneron Pharmaceuticals, Inc. | $54 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2019 | |
| 2019-05-08 | Eli Lilly and Company | $402 | Research payment | In-kind items and services | A PHASE 1A 1B STUDY OF LY3321367, AN ANTI-TIM-3 ANTIBODY, ADMINISTERED ALONE OR IN COMBINATION WITH LY3300054, AN ANTI-P | 2019 | |
| 2019-04-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,505 | Research payment | In-kind items and services | BI754111 & BI754091 BI75411 combination | 2019 | |
| 2019-03-29 | Regeneron Pharmaceuticals, Inc. | $189 | Research payment | In-kind items and services | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2019 | |
| 2019-02-09 | Merck Sharp & Dohme LLC | $7 | Food and Beverage | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-08 | Merck Sharp & Dohme LLC | $50 | Food and Beverage | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-08 | Merck Sharp & Dohme LLC | $31 | Food and Beverage | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-08 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-08 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-07 | Merck Sharp & Dohme LLC | $303 | Travel and Lodging | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-07 | Merck Sharp & Dohme LLC | $82 | Food and Beverage | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-07 | Merck Sharp & Dohme LLC | $63 | Food and Beverage | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-06 | Merck Sharp & Dohme LLC | $303 | Travel and Lodging | In-kind items and services | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-06 | Merck Sharp & Dohme LLC | $95 | Travel and Lodging | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | 2019 | |
| 2019-02-06 | Merck Sharp & Dohme LLC | $52 | Food and Beverage | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Exelixis Inc. | SARAH CANNON RESEARCH | $669 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | University of Oklahoma Health Science Center | $1,644 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $3,000 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-12-23 | Vividion Therapeutics Inc. | Sarah Cannon Research Institute LLC | $2,000 | Services rendered for study VVD25-002 | 2025 |
| 2025-12-18 | Exelixis Inc. | SARAH CANNON RESEARCH | $112 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-12-18 | Exelixis Inc. | SARAH CANNON RESEARCH | $44 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-12-18 | Exelixis Inc. | SARAH CANNON RESEARCH | $43 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-12-18 | Exelixis Inc. | SARAH CANNON RESEARCH | $56 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $3,000 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $5,200 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $1,055 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-12-12 | Exelixis Inc. | SARAH CANNON RESEARCH | $160,132 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $3,000 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-11-19 | Exelixis Inc. | SARAH CANNON RESEARCH | $2,625 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-19 | Exelixis Inc. | SARAH CANNON RESEARCH | $268 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-19 | Exelixis Inc. | SARAH CANNON RESEARCH | $168 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-19 | Exelixis Inc. | SARAH CANNON RESEARCH | $850 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-19 | Exelixis Inc. | SARAH CANNON RESEARCH | $1,372 | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanc | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $3,870 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $3,000 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | Sarah Cannon Research Institute LLC | $450 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2025 |
| 2025-10-31 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-10-31 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $56 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-10-31 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-10-31 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $225 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-10-02 | Roche Products Limited | Sarah Cannon Research Institute LLC | $2,000 | EiH study with WRNinh in MSI dMMR advanced solid tumors | 2025 |
| 2025-10-02 | Roche Products Limited | Sarah Cannon Research Institute LLC | $5,611 | EiH study with WRNinh in MSI dMMR advanced solid tumors | 2025 |
| 2025-10-02 | Roche Products Limited | Sarah Cannon Research Institute LLC | $3,074 | EiH study with WRNinh in MSI dMMR advanced solid tumors | 2025 |
| 2025-10-02 | Roche Products Limited | Sarah Cannon Research Institute LLC | $3,086 | EiH study with WRNinh in MSI dMMR advanced solid tumors | 2025 |
| 2025-10-02 | Roche Products Limited | Sarah Cannon Research Institute LLC | $9,524 | EiH study with WRNinh in MSI dMMR advanced solid tumors | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $45 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,400 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $42 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $75 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $42 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,446 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $897 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $874 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $949 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $876 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $2,785 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $750 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $874 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $655 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $705 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $225 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,432 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $818 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $1,794 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $225 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $42 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $577 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $45 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $30 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Ou Health Stephenson Cancer Center | $22 | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ez | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ponca City, OK, county Kay County, OK, state Oklahoma; placed by its city name.
| Measure | Place (city or town) Ponca City, OK | County Kay County, OK | State Oklahoma |
|---|---|---|---|
| Population B01003 | 24,326 | 43,625 | 4,028,634 |
| Population, 2020 census P1 | 24,424 | 43,700 | 3,959,353 |
| Median age B01002 | 37.1 | 38.5 | 37.0 |
| Under 18 B01001 | 25.6% | 24.8% | 24.0% |
| 65 and over B01001 | 17.7% | 19.4% | 16.3% |
| Households B11001 | 9,371 | 16,776 | 1,562,389 |
| Foreign born B05002 | 3.5% | 3.0% | 6.4% |
| Median household income B19013 | $55,941 | $58,423 | $65,039 |
| Median family income B19113 | $71,919 | $73,504 | $82,385 |
| Per capita income B19301 | $29,992 | $31,071 | $35,624 |
| Poverty rate B17001 | 17.9% | 16.0% | 15.3% |
| Unemployment rate B23025 | 6.9% | 5.8% | 5.0% |
| Civilian labor force B23025 | 11,173 | 19,950 | 1,921,413 |
| Mean commute (minutes) B08013 | 15.7 | 18.9 | 22.4 |
| Bachelor's degree or higher B15003 | 20.6% | 19.2% | 28.3% |
| Housing units B25001 | 11,462 | 20,913 | 1,775,127 |
| Owner-occupied B25003 | 62.5% | 69.2% | 65.8% |
| Renters B25003 | 37.5% | 30.8% | 34.2% |
| Median home value B25077 | $135,800 | $124,700 | $199,800 |
| Median gross rent B25064 | $850 | $842 | $1,014 |
| White, not Hispanic B03002 | 67.8% | 71.2% | 62.1% |
| Black B03002 | 2.9% | 1.8% | 6.8% |
| Hispanic or Latino B03002 | 10.4% | 9.0% | 12.7% |
| Asian B03002 | 0.7% | 0.5% | 2.4% |
| American Indian and Alaska Native B03002 | 6.6% | 6.9% | 6.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ponca City, OK.
Comments